Chief Financial Officer & Head of Technology
Tobin C. Schilke joined Revance as Chief Financial Officer in November of 2018. He brings more than 20 years’ experience in the global biopharma arena, raising capital, completing mergers and acquisitions (M&A) and providing financial leadership in support of commercial enterprises. From 2016 to 2018 Mr. Schilke served as Chief Financial Officer at Achaogen, Inc., where he raised more than $300 million in capital and built teams and capabilities in financial planning and analysis (FP&A), accounting, procurement, IT and facilities management. Previously, he spent 13 years at Roche/Genentech in a variety of finance and operational roles including CFO of Roche Products Limited in the United Kingdom, Director of Commercial FP&A for Genentech’s BioOncology business, and M&A project manager for a number of successful acquisitions, restructurings, and business development initiatives. Mr. Schilke holds a B.S. in Chemical Engineering from Lafayette College, M.S. in Chemical Engineering from University of California, Berkeley, and an M.B.A. from Cornell University.